Comparison of Two-Year Treatment Adherence, Persistence, Discontinuation, Re-initiation, and Switching Between Psoriasis Patients Treated with Ixekizumab or Secukinumab in Real-World Settings

Psoriasis

Comparison of Real-World Treatment Patterns among Psoriasis Patients Prescribed Ixekizumab or Secukinumab

J Am Acad Dermatol.

Blauvelt A, Shi N, Burge R, Malatestinic WN, Lin CY, Lew CR, Zimmerman NM, Goldblum OM, Zhu B, Murage MJ

doi: 10.1016/j.jaad.2019.11.015.

Psoriasis

A multinational, prospective, observational study to estimate complete skin clearance in patients with moderate-to-severe plaque PSOriasis treated with BIOlogics in a REAL world setting (PSO-BIO-REAL)

J Eur Acad Dermatol Venereol.

Seneschal J, Lacour JP, Bewley A, Faurby M, Paul C, Pellacani G, De Simone C, Horne L, Sohrt A, Augustin M, Hammond E, Reich K

doi: 10.1111/jdv.16568.

Psoriasis

Persistence of apremilast in moderate-to-severe psoriasis. A real-world analysis of 14,147 apremilast- and methotrexate-naive patients in the French national health insurance database

Br J Dermatol.

Sbidian E, Billionnet C, Weill A, Maura G, Mezzarobba M

doi: 10.1111/bjd.18047.

Psoriasis

A Comparison of Psoriasis Severity in Pediatric Patients Treated With Methotrexate vs Biologic Agents

JAMA Dermatol.

Bronckers IMGJ, Paller AS, West DP, Lara-Corrales I, Tollefson MM, Tom WL, Hogeling M, Belazarian L, Zachariae C, Mahé E, Siegfried E, Blume-Peytavi U, Szalai Z, Vleugels RA, Holland K, Murphy R, Puig L, Cordoro KM, Lambert J, Alexopoulos A, Mrowietz U, Kievit W, Seyger MMB, Psoriasis Investigator Group, the Pediatric Dermatology Research Alliance, and the European Working Group on Pediatric Psoriasis

doi: 10.1001/jamadermatol.2019.4835.

Psoriasis

Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, exhibits low immunogenicity in psoriasis patients treated up to 5 years

J Eur Acad Dermatol Venereol.

Reich K, Blauvelt A, Armstrong A, Langley RG, de Vera A, Kolbinger F, Spindeldreher S, Ren M, Bruin G

doi: 10.1111/jdv.15637.

Psoriasis

Characteristics and Outcomes of Patients Treated With Apremilast in the Real World: Results From the APPRECIATE Study

J Eur Acad Dermatol Venereol.

Augustin M, Kleyn CE, Conrad C, Sator PG, Ståhle M, Eyerich K, Radtke MA, Bundy C, Mellars L, Greggio C, Cordey M, Koscielny V, Griffiths CEM

doi: 10.1111/jdv.16431.

Psoriatic ArthritisRheumatoid Arthritis

Persistence with golimumab in immune-mediated rheumatic diseases: a systematic review of real-world evidence in rheumatoid arthritis, axial spondyloarthritis, and psoriatic arthritis

Patient Prefer Adherence.

Svedbom A, Storck C, Kachroo S, Govoni M, Khalifa A

doi: 10.2147/PPA.S128665.

Psoriasis

Ixekizumab Survival in Heavily Pretreated Patients with Psoriasis: A Two-year Single-centre Retrospective Study

Acta Derm Venereol

Sherman S, Zloczower O, Noyman Y, Amitay-Laish I, Hodak E, Pavlovsky L

doi: 10.2340/00015555-3714

Psoriasis

The risk of malignancy in secukinumab-treated psoriasis, psoriatic arthritis and ankylosing spondylitis patients: analysis of up to five-year clinical trial and post-marketing surveillance data

Br J Dermatol

Lebwohl M, Deodhar A, Griffiths CEM, Menter MA, Poddubnyy D, Bao W, Jehl V, Marfo K, Primatesta P, Shete A, Trivedi V, Mease PJ

doi: 10.1111/bjd.20136

Related content

Comparison of Real-World Treatment Patterns among Psoriasis Patients Prescribed Ixekizumab or Secukinumab

A multinational, prospective, observational study to estimate complete skin clearance in patients with moderate-to-severe plaque PSOriasis treated with BIOlogics in a REAL world setting (PSO-BIO-REAL)

Persistence of apremilast in moderate-to-severe psoriasis. A real-world analysis of 14,147 apremilast- and methotrexate-naive patients in the French national health insurance database

A Comparison of Psoriasis Severity in Pediatric Patients Treated With Methotrexate vs Biologic Agents

Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, exhibits low immunogenicity in psoriasis patients treated up to 5 years

Characteristics and Outcomes of Patients Treated With Apremilast in the Real World: Results From the APPRECIATE Study

Persistence with golimumab in immune-mediated rheumatic diseases: a systematic review of real-world evidence in rheumatoid arthritis, axial spondyloarthritis, and psoriatic arthritis

Ixekizumab Survival in Heavily Pretreated Patients with Psoriasis: A Two-year Single-centre Retrospective Study

The risk of malignancy in secukinumab-treated psoriasis, psoriatic arthritis and ankylosing spondylitis patients: analysis of up to five-year clinical trial and post-marketing surveillance data